Trial Profile

A Phase II study of Nidlegy™ in patients affected by different nonmelanoma skin cancer indications

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bifikafusp alfa/onfekafusp alfa (Primary)
Indications Basal cell cancer; Cutaneous T-cell lymphoma; Kaposi's sarcoma; Keratoacanthoma; Merkel cell carcinoma; Squamous cell cancer
Focus Therapeutic Use
Sponsors Philogen

Most Recent Events

22 Feb 2022 New trial record
17 Feb 2022 According to a Philogen media release, this study will be conducted under the leadership of Prof. Jean-Jacques Grob.
17 Feb 2022 According to a Philogen media release, the company has received authorization for this study from the France's National Agency for the Safety of Medicines and Health Products (ANSM) and the country's ethic committees (Comite de Protection des Personnes Sud-Est III) has given favorable opinion about the study in January, 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com